The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients | Citedby Results | Oncology | Karger Publishers

Skip to Main Content

Skip Nav Destination

The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients

Oncology (2005) 68 (2-3): 212–216.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis

M. Bouchahda
T. Macarulla
G. LIedo
F. Lévi
M. E. Elez
B. Paule
A. Karaboué
P. Artru
J. Tabernero
D. Machover
P. Innominato
E. Goldschmidt
D. Bonnet
M. Ducreux
V. Castagne
R. Guimbaud

Medical Oncology (2011) 28 (S1): 253.

The integrity of colonic anastomoses following the intraperitoneal administration of oxaliplatin

Konstantinos Blouhos
Manousos-Georgios Pramateftakis
Theodor Tsachalis
Dimitrios Kanellos
Thomas Zaraboukas
Georgios Koliakos
Dimitrios Betsis

International Journal of Colorectal Disease (2010) 25 (7): 835.

Healing of colonic anastomoses after immediate postoperative intraperitoneal administration of oxaliplatin

Dimitrios Kanellos
Manousos-Georgios Pramateftakis
Haralampos Demetriades
Emmanouil Zacharakis
Stamatios Angelopoulos
Ioannis Mantzoros
Ioannis Kanellos
Kalliopi Despoudi
Thomas Zaraboukas
Georgios Koliakos
Kalliopi Galovatsea
Haralampos Lazaridis

International Journal of Colorectal Disease (2008) 23 (12): 1185.